Breast cancer subtypes and the risk of local and regional relapse.

PURPOSE The risk of local and regional relapse associated with each breast cancer molecular subtype was determined in a large cohort of patients with breast cancer. Subtype assignment was accomplished using a validated six-marker immunohistochemical panel applied to tissue microarrays. PATIENTS AND METHODS Semiquantitative analysis of estrogen receptor (ER), progesterone receptor (PR), Ki-67, human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR), and cytokeratin (CK) 5/6 was performed on tissue microarrays constructed from 2,985 patients with early invasive breast cancer. Patients were classified into the following categories: luminal A, luminal B, luminal-HER2, HER2 enriched, basal-like, or triple-negative phenotype-nonbasal. Multivariable Cox analysis was used to determine the risk of local or regional relapse associated the intrinsic subtypes, adjusting for standard clinicopathologic factors. RESULTS The intrinsic molecular subtype was successfully determined in 2,985 tumors. The median follow-up time was 12 years, and there have been a total of 325 local recurrences and 227 regional lymph node recurrences. Luminal A tumors (ER or PR positive, HER2 negative, Ki-67 < 1%) had the best prognosis and the lowest rate of local or regional relapse. For patients undergoing breast conservation, HER2-enriched and basal subtypes demonstrated an increased risk of regional recurrence, and this was statistically significant on multivariable analysis. After mastectomy, luminal B, luminal-HER2, HER2-enriched, and basal subtypes were all associated with an increased risk of local and regional relapse on multivariable analysis. CONCLUSION Luminal A tumors are associated with a low risk of local or regional recurrence. Molecular subtyping of breast tumors using a six-marker immunohistochemical panel can identify patients at increased risk of local and regional recurrence.

[1]  T. Louis,et al.  Statistical analysis of proliferative index data in clinical trials. , 1994, Statistics in medicine.

[2]  V. Goel,et al.  Compliance with practice guidelines for node-negative breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  K. Zedeler,et al.  Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. , 1997, The New England journal of medicine.

[4]  N. Le,et al.  Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. , 1997, The New England journal of medicine.

[5]  C. Louvet.  Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer , 1998 .

[6]  B. Rasmussen,et al.  Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial , 1999, The Lancet.

[7]  Risk factors for local recurrence after breast-conserving therapy for invasive carcinomas: a case-control study of histological factors and alterations in oncogene expression. , 1999 .

[8]  R. Zellars,et al.  Prognostic value of p53 for local failure in mastectomy-treated breast cancer patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[10]  J. Jager,et al.  Anti-apoptotic phenotype is associated with decreased locoregional recurrence rate in breast cancer. , 1998, Anticancer research.

[11]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[12]  M. Fernö,et al.  Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics. , 2001, European journal of cancer.

[13]  T. Hieken,et al.  Predicting the biologic behavior of ductal carcinoma in situ: an analysis of molecular markers. , 2001, Surgery.

[14]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[15]  I. Olivotto,et al.  Age-related variations in the use of axillary dissection: a survival analysis of 8038 women with T1-ST2 breast cancer. , 2002, International journal of radiation oncology, biology, physics.

[16]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[17]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[18]  A. Giatromanolaki,et al.  Molecular analysis of local relapse in high-risk breast cancer patients: can radiotherapy fractionation and time factors make a difference? , 2003, British Journal of Cancer.

[19]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[20]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[21]  A. Goldhirsch,et al.  Minimal and small size invasive breast cancer with no axillary lymph node involvement: the need for tailored adjuvant therapies. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  D. Rimm,et al.  Molecular markers for prognosis after isolated postmastectomy chest wall recurrence , 2004, Cancer.

[23]  I. Olivotto,et al.  Patient subsets with T1-T2, node-negative breast cancer at high locoregional recurrence risk after mastectomy. , 2005, International journal of radiation oncology, biology, physics.

[24]  R. Collins,et al.  Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[25]  S. Bull,et al.  Analysis of incidence and prognostic factors for ipsilateral breast tumour recurrence and its impact on disease-specific survival of women with node-negative breast cancer: a prospective cohort study , 2006, Breast Cancer Research.

[26]  J. Weidhaas,et al.  Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Howard Y. Chang,et al.  Predicting a local recurrence after breast-conserving therapy by gene expression profiling , 2006, Breast Cancer Research.

[28]  D. Easton,et al.  Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival , 2007, Breast Cancer Research.

[29]  Karen A Gelmon,et al.  Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  E. Balk,et al.  Predicting the risk of local recurrence in patients with breast cancer: an approach to a new computer-based predictive tool. , 2006, American journal of clinical oncology.

[31]  S. Narod,et al.  Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.

[32]  J. Wesseling,et al.  p53 overexpression is a predictor of local recurrence after treatment for both in situ and invasive ductal carcinoma of the breast. , 2007, The Journal of surgical research.

[33]  B. Fisher,et al.  Local therapy and survival in breast cancer. , 2007, The New England journal of medicine.

[34]  F. B. Sørensen,et al.  Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  S. Leung,et al.  Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer. , 2008, Clinical breast cancer.

[36]  Barbara L. Smith,et al.  Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  D. Coradini,et al.  Elderly breast cancer patients treated by conservative surgery alone plus adjuvant tamoxifen , 2008, Cancer.

[38]  S. Ménard,et al.  Two Distinct Local Relapse Subtypes in Invasive Breast Cancer: Effect on their Prognostic Impact , 2008, Clinical Cancer Research.

[39]  Samuel Leung,et al.  Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype , 2008, Clinical Cancer Research.

[40]  Charles M. Perou,et al.  Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.

[41]  S. O'toole,et al.  Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.